Experimental study demonstrates tumor growth inhibition using a PEGylated BODIPY photosensitizer, suggesting potential for low-dose photodynamic therapy and afterglow imaging.
Type I photodynamic therapy (PDT) exhibits outstanding therapeutic effects in hypoxic environments in tumors, but the design of type I photosensitizers (PSs), especially those with simple structures but dramatic properties, remains a challenge. Herein, we report a design strategy for developing type I PSs in one molecule with afterglow luminescence. As a proof concept, a 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) PS (BIP) bearing water-soluble poly(ethylene glycol) (mPEG 550 ) chains is synthesized, and BIP can self-assemble into nanoparticles (BIPNs). Interestingly, BIPNs exhibit an O 2 •- -triggered afterglow luminescence, which is scarce, especially for BODIPY derivatives. BIPNs demonstrate outstanding type I dominant PDT at an ultralow dose under both hypoxic and normoxic environments, which can significantly inhibit tumor growth under irradiation. This work highlights a high-performance PS with afterglow luminescence and excellent PDT effects, underscoring the significant potential of versatile PSs in clinical tumor theranostics.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: